ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Protocol ID
ANBL1232
Condition/s
Ganglioneuroblastoma
Neuroblastoma
Diagnosis Stage
Relapse/refractory
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Links
External Registry ≫
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 18 months
International registry ID's
NCT02176967
Back to Registry
Study Title ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
Protocol ID ANBL1232
Disease (Sub Disease) Ganglioneuroblastoma
Neuroblastoma
Diagnosis Stage Relapse/refractory
Sponsor Children's Oncology Group
Collaborators National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT02176967
Trial Status Closed to Recruitment
Trial Open Date 28/07/2014
Study Type Treatment
Phase Phase 3
Age Eligibility up to 18 months
International registry ID's NCT02176967

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.